Tarsus publishes investor presentation on iRenix acquisition, IRX-101 ocular antiseptic program

• Tarsus unveiled its acquisition of iRenix Medical, adding IRX-101 to expand into the retina market.
• Deal terms include USD 75 million upfront consideration split 50% cash, 50% equity.
• Transaction includes up to USD 440 million in approval and commercial milestones, low-to-mid single-digit tiered royalties.
• IRX-101 targets antiseptic-associated pain in intravitreal injection prep; Phase 3 COMFORT study planned for 1H 2027 with topline data in 2028.
• Management highlighted RELIEF study results showing lower mean pain scores versus povidone-iodine, alongside reduced corneal fluorescein staining.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.